Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fcell.2020.00677 http://scihub22266oqcxt.onion/10.3389/fcell.2020.00677 32766256!7379422!32766256     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32766256&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Front+Cell+Dev+Biol 2020 ; 8 (?): 677 Nephropedia Template TP {{tp|p=32766256|t=2020. Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?|pdf=|usr=}}{{32766256}} gab.com Text Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm JO: Front Cell Dev Biol http://www.kidney.de/pget.php?&tw=1&pmid=32766256 #FOAvip Coronavirus disease 2019 (COVID-19) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in tremendous morbidity and mortality worldwide. A major underlying cause of COVID-19 mortality is a hyperinflammatory cytokine storm in severe/critically ill patients. Although many clinical trials are testing the efficacy of targeting inflammatory cytokines/chemokines in COVID-19 patients, the critical inflammatory mediator initiating COVID-19 patient death is undefined. Here we suggest that the immunopathological pathway leading to COVID-19 mortality can be divided into three stages with distinct clinical features that can be used to guide therapeutic strategies. Our interpretation of the recently published clinical trials from COVID-19 patients suggests that the clinical efficacy in preventing COVID-19 mortality using IL-1 blockade is subjected to notable caveats, while that for IL-6 blockade is suboptimal. We discuss critical factors in determining appropriate inflammatory cytokine/chemokine targets, timing, and combination of treatments to prevent COVID-19 mortality. Twit Text FOAVip Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm ????Front Cell Dev Biol http://www.kidney.de/pget.php?&tw=1&pmid=32766256 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32766256 #FOAvip English Wikipedia <ref>{{Cite pmid|32766256}}</ref> Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm? #MMPMID32766256 Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW Front Cell Dev Biol 2020[]; 8 (?): 677 PMID32766256show ga Coronavirus disease 2019 (COVID-19) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in tremendous morbidity and mortality worldwide. A major underlying cause of COVID-19 mortality is a hyperinflammatory cytokine storm in severe/critically ill patients. Although many clinical trials are testing the efficacy of targeting inflammatory cytokines/chemokines in COVID-19 patients, the critical inflammatory mediator initiating COVID-19 patient death is undefined. Here we suggest that the immunopathological pathway leading to COVID-19 mortality can be divided into three stages with distinct clinical features that can be used to guide therapeutic strategies. Our interpretation of the recently published clinical trials from COVID-19 patients suggests that the clinical efficacy in preventing COVID-19 mortality using IL-1 blockade is subjected to notable caveats, while that for IL-6 blockade is suboptimal. We discuss critical factors in determining appropriate inflammatory cytokine/chemokine targets, timing, and combination of treatments to prevent COVID-19 mortality. ?Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in(epmc).pdf DeepDyve Pubget Overpricing